News

Rapiscan, administered as a non-weight based bolus injection, is used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate

Ultimate delivers solutions to a range of industries including pharmaceutical, manufacturing, logistics, chemical, healthcare and the public sector. Barts and London Trust, which consists of three hospitals; St

Aegis claims that Discoverant offers on-demand access, contextualization, analysis and reporting for all manufacturing, quality and process development data. Under the agreement, Shire will utilize Discoverant to manage

NEO-301 specifically binds a variant of the A33 tumor antigen which is a target expressed on the majority of colorectal cancers, and was also found to be expressed

The Series A financing has been led by Adams Street Partners and Latterell Venture Partners. GLYX-13 is a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA

The company has reported a net income of $1.74m, or $0.07 per diluted share, compared to net income of $5.01m or $0.19 per diluted share, for the same

The double-blind, placebo-controlled, six-week clinical trial (with an active comparator) was conducted in Japan, Korea and Taiwan. Subjects were randomized to four arms – placebo (129 subjects), lurasidone

CYT107 is a critical immune-modulator for immune T-cell recovery and enhancement. The study, known as ELYPSE-7, is a randomised, monocentric, double-blind Phase IIa study evaluating the impact of

The company has reported a net loss of $18.4m, compared to net loss of $16.25m, for the same period last year. The company’s loss from operations was $18.54m,